IntelGenx Corp. (TSX VENTURE:IGX) (OTCBB:IGXT) ("IntelGenx") today announced a strategic alliance with LTS Lohmann Therapie-Systeme AG ("LTS") for the exclusive manufacturing of products developed by IntelGenx using its VersaFilm drug delivery technology.
VersaFilm is IntelGenx's immediate release wafer technology. It is comprised of a thin polymeric film using United States Pharmacopeia (USP) components that are safe and approved by the Food and Drug Administration (FDA) for use in food, pharmaceutical and cosmetic products. VersaFilm provides a patent-protected method of re-formulating approved pharmaceuticals in a more convenient and discrete oral dosage form.
In announcing the deal, Dr. Horst G. Zerbe, President and Chief Executive Officer of IntelGenx, said "There are a select few companies capable of manufacturing pharmaceutical films on a global scale in GMP facilities, so we are very pleased to have entered this partnership with LTS, the worldwide leader in film manufacturing. We feel this partnership weds our pharmaceutical film development expertise with LTS's impressive manufacturing capabilities and scope, giving us the necessary tools to successfully develop novel film products from the bench through to regulatory approval. This relationship also strengthens our IP position by combining patents from both companies."
Dr. Zerbe added, "With our most advanced film product having already successfully completed a pilot bioequivalency study and now moving into pivotal studies, our plan is to have LTS begin manufacturing scale up soon."
IntelGenx currently has three products in development using the VersaFilm technology. They are in the process of seeking commercial and development partners for each of them.
Study links poor food diversity in children to higher health costs